HIV drug resistance pattern among HAART-exposed patients with suboptimal virological response in ouagadougou, burkina faso

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 1, 2008, Pages 17-25

  Tebit, Denis M ^a   Sangaré, Lassana ^b   Makamtse, Aline ^b   Yameogo, Saydou ^b   Somlare, Hermann ^b   Bado, Guillaume ^b   Kouldiaty, Boris G ^b   Sathiandee, Kanokporn ^a   Tiba, Fabrice ^a   Sanou, Idrissa ^b   Ouédraogo Traoré, Rasmata ^b   Zoungrana, Lassané ^c   Diallo, Ismael ^c   Drabo, Joseph Y ^c   Kräusslich, Hans Georg ^a,d  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Service de Bacteriologie Virologie   (South Africa)

^c CENTRE HOSPITALIER UNIVERSITAIRE YALGADO OUÉDRAOGO   (Burkina Faso)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Burkina Faso; Drug resistance; HIV

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADOLESCENT; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BURKINA FASO; CHILD; CONTROLLED STUDY; DRUG EXPOSURE; DRUG TREATMENT FAILURE; ENZYME ASSAY; FEMALE; GENE FREQUENCY; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; SCHOOL CHILD; SEQUENCE ANALYSIS; STRAIN DIFFERENCE; TREATMENT RESPONSE; VIRUS STRAIN; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; MUTATION; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BURKINA FASO; CHILD; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; VIRAL LOAD;

EID: 52049116561     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318182d2bc     Document Type: Article

References (28)

1. Los Alamos HIV Database. Available at: http://www.hiv.lanl.gov/content/ hiv-db/CRFs/CRFs.html. Accessed May 15, 2007.
2. Koenig SP, Kuritzkes DR, Hirsch MS, et al. Monitoring HIV treatment in developing countries. BMJ. 2006;332:602-604.
3. Petrella M, Brenner B, Loemba H, et al. HIV drug resistance and implications for the introduction of antiretroviral therapy in resource-poor countries. Drug Resist Updat. 2001;4:339-346.
4. Adje C, Cheingsong R, Roels TH, et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr. 2001;26:501-506.
5. Toni T, Masquelier B, Bonard D, et al. Primary HIV-1 drug resistance in Abidjan (Côte d'Ivoire): a genotypic and phenotypic study. AIDS. 2002; 16:488-491.
6. Kantor R, Zijenah LS, Shafer RW, et al. HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2002;18:1407-1413.
7. Richard N, Juntilla M, Abraha A, et al. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 2004;20: 355-364.
8. Laurent C, Kouanfack C, Vergne L, et al. Antiretroviral drug resistance and routine therapy, Cameroon. Emerg Infect Dis. 2006;12:1001-1004.
9. Chaix ML, Rouet F, Kouakoussui KA, et al. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire. Pediatr Infect Dis J. 2005;24:1072-1076.
10. Arrivé E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-l: a meta-analysis. Int J Epidemiol. 2007;36: 1009-1021.
11. Koizumi Y, Ndembi N, Miyashita M, et al. Emergence of antiretroviral therapy resistance-associated primary mutations among drug-naive HIV-1-infected individuals in rural western Cameroon. J Acquir Immune Defic Syndr. 2006;43:15-22.
12. Ojesina AI, Sankale JL, Odaibo G, et al. Subtype-specific patterns in HIV Type 1 reverse transcriptase and protease in Oyo State, Nigeria: implications for drug resistance and host response. AIDS Res Hum Retroviruses. 2006;22:770-779.
13. Vergne L, Diagbouga S, Kouanfack C, et al. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther. 2006;11: 575-579.
14. Toni T, Masquelier B, Minga A, et al. HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Côte d'Ivoire: a 4-year survey, 2002-2006. AIDS Res Hum Retroviruses. 2007;23:1155-1160.
15. UNAIDS 2006. AIDS Epidemic Update. Available at:http://data.unaids.org/ pub/EpiReport/2006/04-Sub-Saharan-Africa-2006-EpiUpdate-eng.pdf
16. Stanford HIV Drug Resistance Database. Available at:http://hivdb. stanford.edu. Accessed May 15, 2007.
17. Thompson JD, Gibson TJ, Plewniak F, et al. The CLUSTAL X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 1997;25:4876-4882.
18. Tee KK, Kamarulzaman A, Ng KP. Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. Med Microbiol Immunol. 2006;195:107-112.
19. Sen S, Tripathy SP, Patil AA, et al. High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. AIDS Res Hum Retroviruses. 2007;23:1303-1308.
20. Borroto-Esoda K, Parkin N, Miller MD. A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine. Antivir Chem Chemother. 2007;18:297-300.
21. Turner D, Schapiro JM, Brenner BG, et al. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients. Antivir Ther. 2004;9:301-314.
22. Carobene MG, Rubio AE, Carrillo MG, et al. Differences in frequencies of drug resistance-associated mutations in the HIV-1 pol gene of B subtype and BF intersubtype recombinant samples. J Acquir Immune Defic Syndr. 2004;35:207-209.
23. Dumans AT, Soares MA, Machado ES, et al. Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus type 1 subtypes may influence mutational routes to drug resistance. J Infect Dis. 2004;189:1232-1238.
24. Gupta RK, Chrystie IL, O'Shea S, et al. K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients. AIDS. 2005; 19:1916-1919.
25. Kantor R, Katzenstein DA, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005;2:e 112.
26. Novitsky V, Wester CW, DeGruttola V, et al. The reverse transcriptase 67N 70R 215 Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. AIDS Res Hum Retroviruses. 2007;23:868-878.
27. Grossman Z, Vardinon N, Chemtob D, et al. Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS. 2001;15:1453-1460.
28. Gianotti N, Galli L, Boeri E, et al. The 1181 reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2006;41:447-452.